- Clinical Pipeline
- Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
- Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap® PKB/Akt Inhibitor (Oncology)
- KRAS Oncogene (Oncology)
- SHP2 (Oncology)
- P53 tumour suppressor protein (Oncology)
- Clinical Pipeline
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex including three drugs that have now been approved. The responsibility for developing these products is with our partners.
Discovery | Phase 1 | Phase 2 | Phase 3 | Marketed |
---|
Kisqali® (ribociclib)
CDK4/6 inhibitor (Oncology)
Partner: Novartis
. | . | . | . | . |
Balversa® (erdafitinib)
FGFr inhibitor (Oncology)
Partner: Janssen
. | . | . | . | . |
Truqap® (capivasertib)
PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca
. | . | . | . | . |
. | . | . | . |
Other mutants:
. |
Beroterkib (ASTX029)
Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
Partner: Mosaic Therapeutics
. | . | . |
ASTX295
Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Partner: Mosaic Therapeutics
. | . |
SHP2 (Oncology)
Partner: MSD and Taiho
. | . |
P53 (Oncology)
Partner: MSD
. |